SANION fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, and metabolic diseases. Its research focuses on ion channels, which make up of protein that enables and controls the passage of charged ions across cell membranes. Its product pipeline includes Tesofensine, Tesomet, SAN711, and SAN903. The company was founded by Claus Tycho Bræstrup, Anker Gunvald Lundemose, Jørgen Drejer, Palle Christophersen, and Thomas Feldthus in 2011 and is headquartered Glostrup, Denmark.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
SANION does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company